New biologic therapy for systemic lupus erythematosus

Hui Jen Ding, Caroline Gordon

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


Systemic lupus erythematosus (SLE) is a heterogenous multi-systemic autoimmune disease that is associated with considerable morbidity and mortality. Rituximab is one of the earliest biologic therapies used in SLE. It performed well in off-label studies but failed to demonstrate efficacy in randomised controlled trials. Abatacept is a biologic developed for inflammatory arthritis but has shown promise in SLE. Belimumab is the first biologically approved therapy in fifty years for treatment of SLE. The development of biological therapies for SLE parallels the increasing understanding of the immunopathogenesis of SLE and looks promising. New drugs in development are those targeting the co-stimulatory modulation, cytokines and the B and T cells. Of interest are epratuzumab, the interferon antagonists and peptide-based therapies.
Original languageEnglish
Pages (from-to)405-12
Number of pages8
JournalCurrent Opinion in Pharmacology
Issue number3
Publication statusPublished - Jun 2013

Bibliographical note

Copyright © 2013 Elsevier Ltd. All rights reserved.


Dive into the research topics of 'New biologic therapy for systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this